High-Dose Methylprednisolone Treatment-Induced Changes in Immunological Parameters in Progressive Ms Patients

References

• Adachi K., Kumamoto T., Araki S. Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis. Annals of Neurology 1990; 28: 687–691
   PubMed Web of Science ®Google Scholar
• Antel J. P., Arnason B. G. W., Medof M. E. Suppressor cell function in Multiple Sclerosis: correlation with the clinical disease activity. Annals of Neurology 1979; 5: 338–342
   PubMed Web of Science ®Google Scholar
• Antel J. P., Brown-Bania M., Reder A., Cashman M. Activated suppressor cell dysfunction in progressive Multiple Sclerosis. Journal of Immunology 1986; 137: 137–141
   PubMed Web of Science ®Google Scholar
• Arnason B. G. W., Antel J. P. Suppressor cell function in Multiple Sclerosis. Annals of Immunology (Institut Pasteur) 1978; 129C: 159–170
   Google Scholar
• Bansil S., Troiano R., Cook S. D., Rohowsky-Kochan C. Serum soluble interleukin-2 receptor levels in chronic progressive, stable and steroid-treated multiple sclerosis. Acta Neurologica Scandinavica 1991; 84: 282–285
   PubMed Web of Science ®Google Scholar
• Barkhof F., Hommes O. R., Scheltens P., Valk J. Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 1991; 41: 1219–1222
   PubMed Web of Science ®Google Scholar
• Compston D. A. S., Milligan N. M., Hughes P. J., Gibbs J., McBroom V., Morgan B. P., Campbell A. K. A double-blind controlled trial of high-dose methylprednisolone in patients with multiple sclerosis: laboratory results. Journal of Neurology Neurosurgery Psychiatry 1987; 50: 517–522
   PubMed Web of Science ®Google Scholar
• Chung H. T., Samlowski W. E., Daynes R. A. Modification of the immune system by glucocorticosteroids: alterations of the tissue localization properties of circulating lymphocytes. Cellular Immunology 1986; 101: 571–585
   PubMed Web of Science ®Google Scholar
• Crary B., Hauser S. L., Borysenko M., Kutz I., Hoban C., Ault K. A., Howard L. W., Benson H. Epinephrine-induced changes in the distribution of lymphocyte subsets in peripheral blood of humans. Journal of Immunology 1983; 131/3: 1178–1181
   Web of Science ®Google Scholar
• Durelli L., Cocito D., Riccio A., Barile C., Bergamasco B., Baggio G. F., Perla F., Delsedime M., Gusmaroli G., Bergamini L. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 1986; 36: 238–243
   PubMed Web of Science ®Google Scholar
• Durelli L., Poccardi G., Cavallo R. CD8+high CDltb+low T cells (f-suppressor effectors) in multiple sclerosis cerebrospinal fluid are increased during high dose corticosteroid treatment. Journal of Neuroimmunology 1991; 31: 221–228
   PubMed Web of Science ®Google Scholar
• Fauci A. S., Dale D. C. The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. Journal of Clinical Investigation 1974; 53: 240–246
   PubMed Web of Science ®Google Scholar
• Grazzi L., Salmaggi A., Dufour A., Gritti A., Lazzaroni M., Bussone G., Nespolo A., Parati E. Short and medium-term influence of physical activity on immune parameters. International Journal of Neuroscience., in press
   Google Scholar
• Kavanaugh A. F., Lightfoot E., Lipsky P. E., Oppenheimer-Marks N. Role of CD11/ CD18 in adhesion and transendothelial migration of T cells. Journal of Immunology 1991; 146: 4149–4156
   PubMed Web of Science ®Google Scholar
• Kirk P., Compston D. A. S. The effect of methylprednisolone on lymphocyte phenotype and function in patients with multiple sclerosis. Journal of Neuroimmunology 1990; 26: 1–8
   PubMed Web of Science ®Google Scholar
• Kurtzke J. F. Rating neurological impairment in Multiple Sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444–1452
   PubMed Web of Science ®Google Scholar
• McDonald W. I., Halliday A. M. Diagnosis and classification of multiple sclerosis. British Medical Bulletin 1977; 33: 4–8
   PubMed Web of Science ®Google Scholar
• Milligan N. M., Newcombe R., Compston D. A. S. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. clinical effects. Journal of Neurology Neurosurgery Psychiatry 1987; 50: 511–516
   PubMed Web of Science ®Google Scholar
• Morimoto C., Hafler D. A., Weiner H. L., Letvin N. L., Hagan M., Daley J., Schlossman S. F. Selective loss of the suppressor-inducer T-cell subset in progressive multiple sclerosis. New England Journal of Medicine 1987; 316: 67–72
   PubMed Web of Science ®Google Scholar
• Nadler L. M., Anderson K. C., Marti G. B4, a human B lymphocyte associated antigen expressed on normal, mitogen activated and malignant B lymphocytes. Journal of Immunology. 1983; 131: 224–250
   Web of Science ®Google Scholar
• Neighbour P. A., Bloom B. R. Absence of virus-induced lymphocyte suppression and interferon production in Multiple Sclerosis. Proceedings of National Academy of Sciences 1979; 76: 476–480
   PubMed Web of Science ®Google Scholar
• Reder A., Bimbaum G. B-cell differentiation in multiple sclerosis and the effect of intravenous ACTH. Neurology 1983; 33: 442–446
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X., Jafari H. S., Severien C., Parras F., Olsen K. D., Hansen E. J., Singer I. I., McCracken G. H., Jr. Enhanced attenuation of meningeal inflammation and brain edema by concomitant administration of anti-CD 18 monoclonal antibodies and dexamethazone in experimental Haemophilus meningitis. Journal of Clinical Investigation 1991; 88: 2003–2011
   PubMed Web of Science ®Google Scholar
• Trotter J. L., Garvey W. F. Prolonged effects of large-dose methylprednisolone infusion in multiple sclerosis. Neurology 1980; 30: 702–708
   PubMed Web of Science ®Google Scholar
• Trotter J. L., Clifford D. B., Anderson C. B., Van der Veen R. C., Hicks B. C., Banks G. Elevated serum interleukin-2 levels in chronic progressive multiple sclerosis. New England Journal of Medicine 1988; 1206, (letter)
   PubMed Web of Science ®Google Scholar
• Trotter J. L., Clifford D. B., McInnis J. E., Griffeth R. C., Bruns K. A., Perlmutter M. S., Anderson C. A., Collins K. G., Banks G., Hicks B. C. Correlation of immunological studies and disease progression in chronic progressive Multiple Sclerosis. Annals of Neurology 1989; 25: 172–178
   PubMed Web of Science ®Google Scholar
• Tuncer A. M., Ozsoylu S., Ersoy F., Yeniay I. The effects of glucocorticoids on lymphocyte numbers. Immunology Today 1991; 12(6)207, (letter)
   PubMedGoogle Scholar
• Warren K. G., Catz I., Jeffrey V. M., Carroll D. J. Effect of methylprednisolone on CSF IgG parameters, myelin basic protein and anti-myelin basic protein in multiple sclerosis exacerbations. Canadian Journal Neurological Sciences 1986; 13: 25–30
   PubMed Web of Science ®Google Scholar
• Wilcox C. E., Ward A. M. W., Evans A., Baker D., Rothlein R., Turk J. L. Endothelial cell expression of the intercellular adhesion molecule-1 (ICAM-1) in the central nervous system of guinea pigs during acute and chronic relapsing experimental allergic encephalomyelitis. Journal of Neuroimmunology 1990; 30: 43–51
   PubMed Web of Science ®Google Scholar